CD274 and neoplasm: In subcutaneous tumor-bearing model mice injected with SCC-7 cells, the AT-RA-PLGA-PEG-PD-L1 NPs targeted the tumor cells more specifically compared to free ATRA, resulting in enhanced anticancer activity and reduced side effects.